Physician profile
Conor Senecal
NPI 1194104398
$6,652.19
in general payments reported to CMS, 2019-2025
27 companies · $564 in 2025
The $564 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $152 · 2021: $1,254 · 2022: $2,300 · 2023: $1,633 · 2024: $749 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,747 · Travel and Lodging: $1,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,747.45 |
| Travel and Lodging | $1,198.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,954.65 | 2021-2025 | Avvigo Guidance System, Rotapro, Wolverine Coronary Cutting Balloon |
| Biotronik INC. | $746.84 | 2021-2022 | |
| Abiomed | $693.45 | 2020-2025 | Impella |
| Cardiovascular Systems INC. | $440.56 | 2021-2022 | |
| Cook Medical LLC | $424.71 | 2021-2022 | |
| Medtronic, INC. | $378.61 | 2021-2022 | |
| Shockwave Medical, INC | $274.97 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $235.37 | 2024-2025 | |
| Acist Medical Systems, INC. | $197.94 | 2021-2022 | |
| Jenavalve Technology, INC. | $185.13 | 2021 | |
| Abbott Laboratories | $182.08 | 2021-2024 | Cardiomems |
| Astrazeneca Pharmaceuticals LP | $154.75 | 2021-2025 | Farxiga |
| Amgen INC. | $152.77 | 2024-2025 | Repatha, Repatha |
| Terumo Medical Corporation | $116.23 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $74.94 | 2023-2024 | Camzyos |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $67.30 | 2022 | |
| Merck Sharp & Dohme LLC | $61.58 | 2024 | Winrevair |
| Chiesi USA, INC. | $60.05 | 2022-2025 | Kengreal |
| Getinge USA Sales, LLC | $50.96 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.26 | 2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $31.30 | 2024-2025 | |
| Teleflex LLC | $23.94 | 2022 | |
| Heartflow, INC. | $23.90 | 2024 | |
| W. L. Gore & Associates, INC. | $22.35 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.79 | 2024 | Onpattro |
| Kiniksa Pharmaceuticals International, Plc | $17.08 | 2024 | Arcalyst |
| Novo Nordisk INC | $13.68 | 2024 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Conor Senecal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.